From target to patient

- Via mass separation AND radiochemistry

Mikael Jensen
Professor Applied Nuclear Physics
Hevesy Lab, DTU Technical University Denmark

Prismas Map meeting
CERN, Sept. 19, 2019
Hevesy lab has no isotope separator, but:

- High level isotope handling (hotcells, international transport)
- Radiochemistry: Metals, Lanthanides, Halogens
- Long experience with reactor targets
- In house isotope production (commercial and research)
- Two cyclotrons in house and collaboration with the MC32 Copenhagen
- Targetry research
- Our own, in house, GMP radiopharmaceutical production
- Cell radiobiology lab
- Access to small animal imaging labs and a tumor model facility
- Long experience with collaboration industry
- Proven pipe-line: We have over the years managed to develop our own radiopharmaceutical from scratch via clinical trials to routine use.
- Auger emitter research
- Liposomes and hard nanoparticles for therapy
- Cu-64 production (>100 runs/year)
- ICP-OES, ICP-MS
- Mn-52, La-135, direct Ga-68, I-131, I125, Zr-89.....
What we could offer for a consortium

Pre-irradiation preparation of targets
Post irradiation radiochemistry in preparation for the mass separation
Post separation formulation, catcher separation, chelation
In-vitro, in vivo testing

TRAINING!